UNSPSC 51342302: Buciclovir

This classification denotes a purine antagonist and antiviral agent with the molecular formula C9H13N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4G4Z4676IS, chemically known as 6h-purin-6-one, 2-amino-9-(3,4-dihydroxybutyl)-1,9-dihydro-, (r)- but generally known as buciclovir, which bears US NIH Compound Identifier 65648. Buciclovir most often comes in base and triphosphate forms. European Medicines Agency schedules Buciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05943MIG.

UNSPSC 51342302 Buciclovir is a Commodity code that in recent state and local practice covers pharmaceutical supplies and medical products procured for emergency response, public health, and institutional healthcare delivery. The code sees activity across state health departments, county health agencies, municipal fire departments, and cooperative purchasing alliances, with issuing bodies ranging from single-jurisdiction agencies to multi-state procurement vehicles serving dozens of participating entities. Recent solicitations show state and local governments buying naloxone and drug deactivation systems for public health initiatives, generic pharmaceuticals and over-the-counter products through cooperative agreements, and emergency medical supplies for fire department rescue operations—work that spans direct procurement, framework agreements with authorized distributors, and Request for Information exercises to scope future program design.

Recent activity concentrates in Florida, Texas, and the upper Midwest. The City of Tampa issued an ITB (Bid 26P00145) on March 25, 2026, for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a response deadline of March 13, 2026; the procurement is sheltered as a Small Local Business Enterprise set-aside with a 5 percent bid discount. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, to establish multi-vendor contracts for generic pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs prior to issuing a formal RFP.